| abstract |
An IL-17 binding antibody, or one of its fragments, comprising both heavy chain (VH) and light chain (VL) variable domains, for use in the treatment of ankylosing spondylitis, wherein said antibody binding to IL-17, or one of its fragments, comprises at least one antigen-binding site comprising: a) a VH comprising, in sequence, the hypervariable regions CDR1, CDR2 and CDR3, said CDR1 having the amino acid sequence SEQ ID NO: 1, said CDR2 having the amino acid sequence SEQ ID NO: 2, and said CDR3 having the amino acid sequence SEQ ID NO: 3, wherein said hypervariable regions are in accordance with the definition of Kabat; or a VH comprising, in sequence, the hypervariable regions CDR1-x, CDR2-x and CDR3-x, said CDR1-x having the amino acid sequence SEQ ID NO: 11, said CDR2-x having the amino acid sequence SEQ ID NO: 12, and said CDR3-x having the amino acid sequence SEQ ID NO: 13, wherein said hypervariable regions are in accordance with the definition of Chothia; and b) a VL comprising, in sequence, the hypervariable regions CDR1 ', CDR2' and CDR3 ', said CDR1' having the amino acid sequence SEQ ID NO: 4, said CDR2 'having the amino acid sequence SEQ ID NO: 5, and said CDR3 'having the amino acid sequence SEQ ID NO: 6. |